ArticleThe Journal of infectious diseases2026
Association Between Female Genital Schistosomiasis and High-Risk Human Papillomavirus Among Women of Reproductive Age in Zambia: The Schista Study.
Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
backgroundFemale genital schistosomiasis (FGS), a gynecological disease caused by Schistosoma haematobium egg deposition in the female genital tract, is prevalent in sub-Saharan Africa, the region with the highest cervical cancer burden globally. Persistent high-risk human papillomavirus (HR-HPV) infection is necessary for cervical cancer development. We determined the association between FGS and HR-HPV genotypes in Zambian women.
methodsSexually active women aged 15-50 years, not menstruating or pregnant, were recruited at home and provided 2 cervicovaginal self-swabs, urine sample, and HIV and Trichomonas vaginalis self-tests, and completed a questionnaire. In clinic, midwives collected cervicovaginal swabs and cervical images with point-of-care colposcopy (EVA System, MobileODT). Swabs were analyzed for 14 HR-HPV types (GeneXpert) and Schistosoma DNA (ITS-2 real-time polymerase chain reaction [qPCR]); urine was analyzed for Schistosoma ova by microscopy and circulating anodic antigen. Visual FGS was defined as colposcopic identification of specific genital lesions, and molecular FGS as Schistosoma-positive cervicovaginal qPCR.
resultsAmong 2532 women (median age, 28 [interquartile range, 22-36] years) recruited at home, 1694 (67%) completed clinic follow-up. Prevalence of visual FGS, molecular FGS, and HR-HPV was 35.2% (595/1691), 6.5% (165/2532), and 28.7% (690/2401), respectively. Molecular FGS was weakly associated with all HR-HPV (adjusted odds ratio [aOR], 1.3 [95% confidence interval {CI}, .9-1.9]). Women with molecular FGS were more likely to test positive for HR-HPV types 16/18/45 (aOR, 1.7 [95% CI, 1.0-2.8]). No association was observed between visual FGS and HR-HPV infection (95% CI, .7-1.1).
conclusionsThis is the first study to jointly screen for FGS and HR-HPV in Zambia, reporting an association between oncogenic HR-HPV types and molecular FGS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.